Copenhagen-based digital health company Dawn Health has secured $13 million (€11.5 million) in funding from existing investors Chr. Augustinus Fabrikker, the Export and Investment Fund of Denmark (EIFO), and Trifork to expand its chronic disease management platform globally.

The company's platform leverages advanced capabilities in artificial intelligence, data analytics, evidence generation, clinical integrations, personalization, and connected health technologies. Dawn Health's solutions are currently deployed across multiple therapeutic areas including oncology, multiple sclerosis, and rare pediatric conditions such as growth disorders.

Major pharmaceutical companies including Merck and Novartis have already adopted Dawn's offerings. With this new funding, Dawn Health aims to market its platform and product suite to more global pharmaceutical companies through a software-as-a-service (SaaS) model.

"Our ambition is to be the global leader in digital health, powering pharma's next-generation products and ultimately improving the lives of patients worldwide," Alexander Mandix Hansen, CEO of Dawn Health, said in a statement. "This funding allows us to bring our proven platform to more markets and deepen our impact."

The investment comes after Dawn Health's strategic partnership with Novartis in 2023 to develop a comprehensive chronic condition management platform. This collaboration focused on building remote monitoring and management tools for conditions with unmet needs and concerns around disease progression, including multiple sclerosis, hypertension, cardiovascular disease, and breast cancer.

The platform developed through this partnership features patient mobile apps, symptom monitoring capabilities, digital biomarkers, clinical decision support services, and virtual clinic offerings tailored to specific diseases and conditions.

Dawn Health operates in an increasingly competitive digital chronic condition management space. Other notable companies in this sector include Wellth, which secured $20 million in Series B funding in 2023 led by SignalFire, and Omada Health, which raised $192 million in Series E funding in 2022 led by Fidelity Management & Research Company.

Omada Health has expanded its platform to include behavioral health support alongside its existing programs for diabetes prevention and management, hypertension, and musculoskeletal care, demonstrating the trend toward more comprehensive digital health solutions in chronic disease management.